Fluciclovine PET/CT in Multiple Myeloma Patients

PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03966443

Acronym

FLUCIPET

Enrollment

Registered

2019-05-29

Start date

2019-03-01

Completion date

2029-01-31

Last updated

2019-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloma, Multiple, PET-CT

Brief summary

Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Multiple myeloma patients suitable for ASCT treatment

Exclusion criteria

* Patients with contraindications to ASCT treatment

Design outcomes

Primary

Measure	Time frame
Comparing of image findings at PET	1 year

Countries

Norway

Contacts

Primary ContactMona-Elisabeth Revheim, MD, PhD, MHA

monar@ous-hf.no+4790659373

Outcome results